Keyword: Oxford University
Allergan taps Celgene vet Bob Hugin for M&A guidance; Imara gains a Pfizer rare disease exec as CMO; and iTeos brings on Sanofi cancer VP as CMO.
The series B, which attracted the support of GV, sets Evox up to take rare disease candidates into the clinic.
Pfizer has set up a new partnering network to try to foster collaborations with top-tier universities
This past week ushered in new developments in the fight against retinitis pigmentosa, heart failure and pancreatic cancer.
Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
German CRO-biotech hybrid Evotec and England’s Oxford University have granted their first set of awards that will help fund projects targeting CV and infectious diseases, with more to come in the summer.
OxStem has closed a £16.9 million fundraising round to design stem cell drugs that treat age-related diseases.
Patients with a rare eye disease that causes blindness saw their sight improve in the long term with the use of a new gene therapy.